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blood and breast milk is based on modelling, animal experi-
ments and clinical observations due to lack of experimental
evidence in humans.Wedescribe the use of doxazosin in a preg-
nant woman with a phaeochromocytoma. Treatment of a
phaeochromocytoma in pregnancy consists of α-adrenergic
receptor blockade followed by surgical excision either during
pregnancy or directly after delivery. We measured doxazosin
concentrations before and after delivery inmaternal and umbil-
ical cord blood sampled from the umbilical vein and breastmilk
using a validated toxicology liquid chromatography-mass
spectrometry method. The patient approved these additional
tests and publication of her case.
A 35-year-old Caucasian woman (gravida 3, para 2; two ﬁrst
pregnancies without complications) was diagnosed as having a
phaeochromocytoma in her right adrenal gland at the end of
the second trimester of pregnancy. Her blood pressure was
well-controlled using doxazosin 4 mg once daily, probably as a
consequence of only mildly elevated catecholamines. Because
of the advanced pregnancy we decided to follow-up in the
outpatient setting with regular home blood pressure measure-
ments. At week 37, she was admitted to the hospital for intensi-
ﬁcation of her antihypertensive therapy prior to induction of
labour at week 38 (+2 days). Her mean arterial blood pressure
(MAP) was targeted to be ≤100 mmHg.
A 24 hr blood pressure measurement showed a mean MAP
during daytime of 104 mmHg. The doxazosin dosage was
increased (Table 1) and metoprolol 12.5 mg was added 2 days be-
fore delivery because of tachycardia (heart rate> 100 beatsmin–1).
Vaginal delivery was without complications.
A boy was born with a good start (Apgar score of 9 and 10
after 1 and 5 min) and a birth weight of 4210 g. Physical
examination did not show any abnormalities including
dysmorphic features and kidney function was normal. He© 2016 The AuthoDOI:10.1111/bcp.12981
This is an open access article under the terms of the Creative Commons Attribution-
medium, provided the original work is properly cited, the use is non-commercial andwas monitored at the neonatal intensive care unit for 30 h. His
blood pressure, measured every hour, was normal, MAP around
50 mm Hg. Three days after delivery, his mother underwent
adrenalectomy. The diagnosis of a phaeochromocytoma with a
diameter of 7.5 cm was conﬁrmed. Directly after surgery,
doxazosin and metoprolol were stopped.
Based on the small molecular size but high level of protein
binding (98%) it was hard to make a prediction about the
placental transfer of doxazosin. We hypothesized that it would
be limited, based on data in rabbits and rats and no reported
serious adverse events in human newborns [1]. In our
patient,we found a doxazosin fetal :maternal ratio of 0.8, indicat-
ing exposure of the fetus to therapeutic doxazosin concentrations
(Table 1). One could argue that some placental transfer of an α-
adrenergic receptor blocker is appropriate to prevent adrenergic
stimulation of the fetus. However, earlier studies in phaeo-
chromocytoma during pregnancy and one unpublished case in
our hospital showed low levels of catecholamines (adrenaline
and norepinephrine) in umbilical cord blood (<10% of maternal
levels) [2]. This is due to high activity of catecholamine trans-
porters (most importantly: norepinephrine transporters) and
metabolizing enzymes such as catechol-O-methyltransferase in
the placenta probably to protect the fetus against elevated cate-
cholamine levels during delivery [2]. The umbilical cord plasma
concentrations of metanephrine and normetanephrine we mea-
sured were approximately half of the maternal levels (Table 1).
We do not know whether these levels were completely of fetal
origin or also in part from maternal origin, following crossing of
the placenta of either free metanephrines or rapidly degraded
catecholamines.
The other α-adrenergic receptor blocker that has been used
during pregnancy is phenoxybenzamine that binds irreversibly
[3]. The fetal : maternal plasma ratio of phenoxybenzamine is
1.6, suggesting accumulation in the fetus. Neonatal hypotensionrs. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd
on behalf of The British Pharmacological Society.
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Table 1
Plasma concentrations of doxazosin and (nor)metanephrine at different time points
Doxazosin
dose (mg)
a.m. p.m. Plasma
Doxazosin
(μg l–1)
Metanephrine
(nmol l–1)
Normetanephrine
(nmol l–1)
1 month 4 mg - Maternal 1.15 6.9
1 week (hospital admission) 6 mg
3 days 6 mg 2 mg Maternal 45 (peak concentration)
Day 0 (delivery) 6 mg 2 mg Maternal 48 (12 h after drug intake) 1.23 6.8
Umbilical 40 0.48 3.77
+2 days 6 mg 4 mg Maternal 72 (trough concentration)
+3 days (surgery) 8 mg - Maternal 95 (trough concentration)
+2 weeks - - Maternal <0.06 0.22
Therapeutic range for trough concentration of doxazosin: 10–150 μg l–1. Lower limit of quantiﬁcation plasma assay 25 μg l–1. Metanephrine normal
<0.3 nmol l–1; Normetanephrine normal <0.6 nmol l–1
Letter to the Editorand respiratory depression after maternal use of phenoxyben-
zamine during pregnancy has been reported, although in this
case report the mother also used a low dose of labetalol and in
most cases also phenoxybenzamine appeared safe [4].
Doxazosin has earlier been described to transfer into breast
milk [5]. Our ﬁrst breast milk sample (mixed foremilk and
hindmilk) could be obtained 30 h after the last dose and did
not show any doxazosin disposition. Given the plasma half-life
of 16–30 h, maternal plasma concentrations of doxasozin are
expected to be still in the therapeutic range at that time. There-
fore, we assume that transfer into breast milk was low during
doxazosin use. Also for phenoxybenzamine a low percentage
of transfer into breastmilk has been described, around 1% [1, 3].
Our results support earlier evidence that doxazosin is a
safe α-adrenegic receptor blocker to use in pregnant women
with a phaeochromocytoma. Although it passes the placenta,
the fetal drug concentration remained lower than the
maternal concentration, at least for the relatively low dose
of 8 mg. We cannot recommend its use during breastfeeding,
but based on our data it seems safe to start breastfeeding 1 day
after the last doxazosin dose.Competing Interests
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